Sequence 8 from Patent US 20060122119

General Information


DRACP ID  DRACP01256

Peptide Name   Sequence 8 from Patent US 20060122119

Sequence  EAAGIGILTV

Sequence Length  10

UniProt ID  Q16655  A7MQM1 

PubChem CID  Not available

Origin  Homo sapiens

Type  Native peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Antitumor



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01256

Helicity  Not available

Linear/Cyclic  Not available

Disulfide/Other Bond  Not available

N-terminal Modification  Not available

C-terminal Modification  Not available

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C42H74N10O14

Absent amino acids  CDFHKMNPQRSWY

Common amino acids  AGI

Mass  110384

Pl  3.85

Basic residues  0

Acidic residues  1

Hydrophobic residues  6

Net charge  -1

Boman Index  1492

Hydrophobicity  156

Aliphatic Index  166

Half Life 
  Mammalian: 1 hour
  Yeast: 30 min
  E.coli: >10 hour

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  3

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 2006/0122119 A1

Patent Title  Peptides for use in antitumor immunotherapy.

Other Iinformation  Granted Patent Family: 10s / 10ex; Family Jurisdictions: CA, AU, FR, WO, US, EP, JP; Legal Status: Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002

Other Published ID  CA2477762A1  EP1481009A2  WO2003074565A2  WO2003074565A3 




DRACP is developed by Dr.Zheng's team.